This is the authors' abstract. We don't add key points for this paper.
as well as showcase recent advances in decellularization and processing methodologies that have been explored across different scales and diverse biological complexities. The incorporation of cdECM into the design stages of bioengineered tumor models and its biological relevance are also discussed considering currently available alternatives to model tumor ECM. Finally, we look at the current challenges in using cdECM-based biomaterials to develop preclinically relevant models and discuss the need for innovative production approaches and methodological developments in downstream processing to widen the use of cell-derived biomaterials for tumor modelling and other applications in the tissue engineering field.
No takes yet. Share an insight, caveat, or question.
Rodrigues et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: